Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED)

Published on June 30, 2026
WALTHAM, Mass.—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company, announced that the Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). Lumvoa was approved by the FDA under priority review and supported by the THRIVE (active TED) and THRIVE-2 (chronic TED) pivotal phase 3 clinical trials. “With the approval of Lumvoa, we take a significant step forward in providing a meaningful treatment option for people living with thyroid eye disease,” said Steve Mahoney, president and CEO of Viridian.
Continue reading on website
Other news

The Vision Council Foundation Celebrates National Sunglasses Day With In-Person Events, Industry Outreach

June 30, 2026
ALEXANDRIA, Va.—This past Saturday, June 27, was National Sunglasses Day, which saw The Vision Council Foundation deliver the message of UV eye protection to fitness classes, an outdoor market, a trade show and over 50 optical shops across the United States, asserting that eye protection is a core part of a healthy lifestyle, the Foundation said in an announcement. The Vision Council Foundation’s

LensCrafters Launches Vision & Eye Health Center, Integrated Ecosystem Includes Medical Services, Surgical Procedures

June 30, 2026
NEW YORK—LensCrafters, part of EssilorLuxottica and a leading North American retail brand, today announces the launch of the first LensCrafters Vision & Eye Health Center, introducing premium comprehensive eyecare and surgical solutions in a modern, patient-centric environment. The center is located in Exton, Pa., and represents the first step within LensCrafters’ North American growth strategy,